Physician profile
Konstantinos Tripodis
NPI 1588698534
$1,036,705.05
in general payments reported to CMS, 2019-2025
12 companies · $242K in 2025
The $242K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $154K · 2020: $52K · 2021: $84K · 2022: $166K · 2023: $147K · 2024: $192K · 2025: $242K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $506K · Consulting Fee: $33K · Travel and Lodging: $24K · Food and Beverage: $19K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $505,694.40 |
| Consulting Fee | $32,763.00 |
| Travel and Lodging | $23,852.68 |
| Food and Beverage | $18,946.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $359,428.32 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $182,144.40 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160,934.01 | 2020-2025 | Caplyta |
| Teva Pharmaceuticals USA, INC. | $125,208.25 | 2022-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $122,069.52 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Janssen Pharmaceuticals, INC | $66,213.15 | 2019-2022 | |
| Allergan, INC. | $16,749.40 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $3,024.73 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $480.67 | 2024-2025 | Cobenfy |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $241.40 | 2019-2023 | Abilify Asimtufii |
| Janssen Scientific Affairs, LLC | $149.73 | 2019-2022 | |
| Lundbeck LLC | $61.47 | 2021-2025 | Abilify Asimtufii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Konstantinos Tripodis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.